Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013

Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for E...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2015-06, Vol.59 (6), p.3606-3610
Main Authors: Lob, Sibylle H, Kazmierczak, Krystyna M, Badal, Robert E, Hackel, Meredith A, Bouchillon, Samuel K, Biedenbach, Douglas J, Sahm, Daniel F
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
beta-Lactamases - genetics
beta-Lactamases - metabolism
beta-Lactams
beta-Lactams - pharmacology
Escherichia coli
Escherichia coli - drug effects
Escherichia coli - enzymology
Genotype
Humans
Intraabdominal Infections
Intraabdominal Infections - microbiology
Microbial Sensitivity Tests
Susceptibility
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63
cites cdi_FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63
container_end_page 3610
container_issue 6
container_start_page 3606
container_title Antimicrobial agents and chemotherapy
container_volume 59
creator Lob, Sibylle H
Kazmierczak, Krystyna M
Badal, Robert E
Hackel, Meredith A
Bouchillon, Samuel K
Biedenbach, Douglas J
Sahm, Daniel F
description Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for Escherichia coli isolates from patients with intra-abdominal infections. In the subset of isolates from community-associated infections, susceptibility to levofloxacin decreased significantly and the increasing rate of multidrug-resistant E. coli approached statistical significance. In 2013, ertapenem, imipenem, and amikacin showed the highest susceptibility rates (≥99%) and fluoroquinolones the lowest (
doi_str_mv 10.1128/aac.05186-14
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4432174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25801558</sourcerecordid><originalsourceid>FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63</originalsourceid><addsrcrecordid>eNp1kU9r3DAQxUVpaLZpbz0XXQtxKtmSbF8Ky5L-gZRAsjmLsTTeVbAlI2kD-WD9frWzaWgPPQ2Dfu_NaB4hHzi74LxsPgOYCyZ5owouXpEVZ21TKNmq12TFmFKFaJg4JW9TumdzL1v2hpyWsmFcymZFfm0jepuo8zQdksEpu84NLj_S0NPLZPYYndk7oCYMjvYxjDOaIxTQ2TA6D8Pc92iyCz7RHCjGDBN6HCl4O6vGCSLkEJ9G5D3SO-8yWnqbIWOiYEyI1vndorWQ4ThjAW9_rm-2dIphF2E8pyVj7QKVjFfvyEkPQ8L3z_WM3H293G6-F1fX335s1lcFiFbkosWqV51EIaGci5rPVLUtx8ZK1oMVZd1j3dSK1QKF5cBMZSUI1nFlubSqOiNfjr7ToRvRGly-PugpuhHiow7g9L8v3u31LjxoIaqS12I2OD8amBhSiti_aDnTS3x6vd7op_g0X_BPRxzSWOr7cIjzgdP_2I9_7_Zi_Cfb6jdEGqVt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>Lob, Sibylle H ; Kazmierczak, Krystyna M ; Badal, Robert E ; Hackel, Meredith A ; Bouchillon, Samuel K ; Biedenbach, Douglas J ; Sahm, Daniel F</creator><creatorcontrib>Lob, Sibylle H ; Kazmierczak, Krystyna M ; Badal, Robert E ; Hackel, Meredith A ; Bouchillon, Samuel K ; Biedenbach, Douglas J ; Sahm, Daniel F</creatorcontrib><description>Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for Escherichia coli isolates from patients with intra-abdominal infections. In the subset of isolates from community-associated infections, susceptibility to levofloxacin decreased significantly and the increasing rate of multidrug-resistant E. coli approached statistical significance. In 2013, ertapenem, imipenem, and amikacin showed the highest susceptibility rates (≥99%) and fluoroquinolones the lowest (&lt;70%). The 10 non-ertapenem-susceptible isolates (0.3% of all E. coli isolates) encoded one or more carbapenemases, extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, or non-ESBL β-lactamases.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/aac.05186-14</identifier><identifier>PMID: 25801558</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Anti-Bacterial Agents ; Anti-Bacterial Agents - pharmacology ; beta-Lactamases - genetics ; beta-Lactamases - metabolism ; beta-Lactams ; beta-Lactams - pharmacology ; Escherichia coli ; Escherichia coli - drug effects ; Escherichia coli - enzymology ; Genotype ; Humans ; Intraabdominal Infections ; Intraabdominal Infections - microbiology ; Microbial Sensitivity Tests ; Susceptibility ; United States</subject><ispartof>Antimicrobial agents and chemotherapy, 2015-06, Vol.59 (6), p.3606-3610</ispartof><rights>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</rights><rights>Copyright © 2015, American Society for Microbiology. All Rights Reserved. 2015 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63</citedby><cites>FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.05186-14$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.05186-14$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,27924,27925,52751,52752,52753,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25801558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lob, Sibylle H</creatorcontrib><creatorcontrib>Kazmierczak, Krystyna M</creatorcontrib><creatorcontrib>Badal, Robert E</creatorcontrib><creatorcontrib>Hackel, Meredith A</creatorcontrib><creatorcontrib>Bouchillon, Samuel K</creatorcontrib><creatorcontrib>Biedenbach, Douglas J</creatorcontrib><creatorcontrib>Sahm, Daniel F</creatorcontrib><title>Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for Escherichia coli isolates from patients with intra-abdominal infections. In the subset of isolates from community-associated infections, susceptibility to levofloxacin decreased significantly and the increasing rate of multidrug-resistant E. coli approached statistical significance. In 2013, ertapenem, imipenem, and amikacin showed the highest susceptibility rates (≥99%) and fluoroquinolones the lowest (&lt;70%). The 10 non-ertapenem-susceptible isolates (0.3% of all E. coli isolates) encoded one or more carbapenemases, extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, or non-ESBL β-lactamases.</description><subject>Anti-Bacterial Agents</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>beta-Lactamases - genetics</subject><subject>beta-Lactamases - metabolism</subject><subject>beta-Lactams</subject><subject>beta-Lactams - pharmacology</subject><subject>Escherichia coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - enzymology</subject><subject>Genotype</subject><subject>Humans</subject><subject>Intraabdominal Infections</subject><subject>Intraabdominal Infections - microbiology</subject><subject>Microbial Sensitivity Tests</subject><subject>Susceptibility</subject><subject>United States</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU9r3DAQxUVpaLZpbz0XXQtxKtmSbF8Ky5L-gZRAsjmLsTTeVbAlI2kD-WD9frWzaWgPPQ2Dfu_NaB4hHzi74LxsPgOYCyZ5owouXpEVZ21TKNmq12TFmFKFaJg4JW9TumdzL1v2hpyWsmFcymZFfm0jepuo8zQdksEpu84NLj_S0NPLZPYYndk7oCYMjvYxjDOaIxTQ2TA6D8Pc92iyCz7RHCjGDBN6HCl4O6vGCSLkEJ9G5D3SO-8yWnqbIWOiYEyI1vndorWQ4ThjAW9_rm-2dIphF2E8pyVj7QKVjFfvyEkPQ8L3z_WM3H293G6-F1fX335s1lcFiFbkosWqV51EIaGci5rPVLUtx8ZK1oMVZd1j3dSK1QKF5cBMZSUI1nFlubSqOiNfjr7ToRvRGly-PugpuhHiow7g9L8v3u31LjxoIaqS12I2OD8amBhSiti_aDnTS3x6vd7op_g0X_BPRxzSWOr7cIjzgdP_2I9_7_Zi_Cfb6jdEGqVt</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Lob, Sibylle H</creator><creator>Kazmierczak, Krystyna M</creator><creator>Badal, Robert E</creator><creator>Hackel, Meredith A</creator><creator>Bouchillon, Samuel K</creator><creator>Biedenbach, Douglas J</creator><creator>Sahm, Daniel F</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150601</creationdate><title>Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013</title><author>Lob, Sibylle H ; Kazmierczak, Krystyna M ; Badal, Robert E ; Hackel, Meredith A ; Bouchillon, Samuel K ; Biedenbach, Douglas J ; Sahm, Daniel F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-Bacterial Agents</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>beta-Lactamases - genetics</topic><topic>beta-Lactamases - metabolism</topic><topic>beta-Lactams</topic><topic>beta-Lactams - pharmacology</topic><topic>Escherichia coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - enzymology</topic><topic>Genotype</topic><topic>Humans</topic><topic>Intraabdominal Infections</topic><topic>Intraabdominal Infections - microbiology</topic><topic>Microbial Sensitivity Tests</topic><topic>Susceptibility</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lob, Sibylle H</creatorcontrib><creatorcontrib>Kazmierczak, Krystyna M</creatorcontrib><creatorcontrib>Badal, Robert E</creatorcontrib><creatorcontrib>Hackel, Meredith A</creatorcontrib><creatorcontrib>Bouchillon, Samuel K</creatorcontrib><creatorcontrib>Biedenbach, Douglas J</creatorcontrib><creatorcontrib>Sahm, Daniel F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lob, Sibylle H</au><au>Kazmierczak, Krystyna M</au><au>Badal, Robert E</au><au>Hackel, Meredith A</au><au>Bouchillon, Samuel K</au><au>Biedenbach, Douglas J</au><au>Sahm, Daniel F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>59</volume><issue>6</issue><spage>3606</spage><epage>3610</epage><pages>3606-3610</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Antimicrobial resistance in Enterobacteriaceae, including resistance to carbapenems, is increasing worldwide. However, using U.S. Study for Monitoring Antimicrobial Resistance Trends (SMART) data for 2009 to 2013, no statistically significant decreasing susceptibility trends were found overall for Escherichia coli isolates from patients with intra-abdominal infections. In the subset of isolates from community-associated infections, susceptibility to levofloxacin decreased significantly and the increasing rate of multidrug-resistant E. coli approached statistical significance. In 2013, ertapenem, imipenem, and amikacin showed the highest susceptibility rates (≥99%) and fluoroquinolones the lowest (&lt;70%). The 10 non-ertapenem-susceptible isolates (0.3% of all E. coli isolates) encoded one or more carbapenemases, extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, or non-ESBL β-lactamases.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>25801558</pmid><doi>10.1128/aac.05186-14</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2015-06, Vol.59 (6), p.3606-3610
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4432174
source American Society for Microbiology Journals; PubMed Central
subjects Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
beta-Lactamases - genetics
beta-Lactamases - metabolism
beta-Lactams
beta-Lactams - pharmacology
Escherichia coli
Escherichia coli - drug effects
Escherichia coli - enzymology
Genotype
Humans
Intraabdominal Infections
Intraabdominal Infections - microbiology
Microbial Sensitivity Tests
Susceptibility
United States
title Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T12%3A26%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trends%20in%20susceptibility%20of%20Escherichia%20coli%20from%20intra-abdominal%20infections%20to%20ertapenem%20and%20comparators%20in%20the%20United%20States%20according%20to%20data%20from%20the%20SMART%20program,%202009%20to%202013&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Lob,%20Sibylle%20H&rft.date=2015-06-01&rft.volume=59&rft.issue=6&rft.spage=3606&rft.epage=3610&rft.pages=3606-3610&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/aac.05186-14&rft_dat=%3Cpubmed_cross%3E25801558%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a494t-9e3f6b5e45a2b5e60513991e8d50fad427fe7876074e4d1a0c3d5a40b16d15d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/25801558&rfr_iscdi=true